Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.
about
Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo.Factors that affect PERCIST-defined test-retest comparability: an exploration of feasibility in routine clinical practice.Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma.Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinomaEvaluation of prognostic markers for patients with curatively resected thoracic esophageal squamous cell carcinomas.Quality of life after esophageal resection.
P2860
Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Trimodality therapy of esophag ...... arcinoma patients.
@ast
Trimodality therapy of esophag ...... arcinoma patients.
@en
type
label
Trimodality therapy of esophag ...... arcinoma patients.
@ast
Trimodality therapy of esophag ...... arcinoma patients.
@en
prefLabel
Trimodality therapy of esophag ...... arcinoma patients.
@ast
Trimodality therapy of esophag ...... arcinoma patients.
@en
P2093
P2860
P356
P1433
P1476
Trimodality therapy of esophag ...... arcinoma patients.
@en
P2093
Kotaro Kitani
Masanori Tsujie
Masao Yukawa
Masatoshi Inoue
Norihiko Kamikonya
Reigetsu Yoshikawa
Takehira Yamamura
Tsuyoshi Nakayama
Yoshinori Fujiwara
P2860
P304
P356
10.3892/OR.2012.1847
P577
2012-06-01T00:00:00Z